Sofia Haque
Memorial Sloan Kettering Cancer Center
103 Papers
349 Citations
Sofia Haque is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 25, co-authored 87 publications. Previous affiliations of Sofia Haque include NewYork–Presbyterian Hospital & Emory University.
Chat about Author
Papers
Selumetinib-Enhanced Radioiodine Uptake in Advanced Thyroid Cancer
Alan L. Ho,Ravinder K. Grewal,Rebecca Leboeuf,Eric J. Sherman,David G. Pfister,Désirée Deandreis,Keith S. Pentlow,Pat Zanzonico,Sofia Haque,Somali Gavane,Ronald Ghossein,Julio C. Ricarte-Filho,José Carlos de Miguel Domínguez,Ronglai Shen,R. Michael Tuttle,Steve Larson,James A. Fagin +16 more
TL;DR: Selumetinib produces clinically meaningful increases in iodine uptake and retention in a subgroup of patients with thyroid cancer that is refractory to radioiodine; the effectiveness may be greater in patients with RAS-mutant disease.
Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial.
Jason Fangusaro,Arzu Onar-Thomas,Tina Young Poussaint,Shengjie Wu,Azra H. Ligon,Neal I. Lindeman,Anuradha Banerjee,Roger J. Packer,Lindsay Kilburn,Stewart Goldman,Ian F. Pollack,Ibrahim Qaddoumi,Regina I. Jakacki,Paul G. Fisher,Girish Dhall,Patricia Baxter,Susan G. Kreissman,Clinton F. Stewart,David T.W. Jones,Stefan M. Pfister,Gilbert Vezina,Jessica S Stern,Ashok Panigrahy,Zoltan Patay,Benita Tamrazi,Jeremy Jones,Sofia Haque,David S. Enterline,Soonmee Cha,Michael Fisher,Laurence Austin Doyle,Malcolm A. Smith,Ira J. Dunkel,Maryam Fouladi +33 more
TL;DR: Results show that selumetinib could be an alternative to standard chemotherapy for these subgroups of patients, and have directly led to the development of two Children's Oncology Group phase 3 studies comparing standard chemotherapy to selumsentinib in patients with newly diagnosed paediatric low-grade glioma both with and without NF1.
Convection-enhanced delivery for diffuse intrinsic pontine glioma: a single-centre, dose-escalation, phase 1 trial
Mark M. Souweidane,Mark M. Souweidane,Kim Kramer,Kim Kramer,Neeta Pandit-Taskar,Neeta Pandit-Taskar,Zhiping Zhou,Zhiping Zhou,Sofia Haque,Sofia Haque,Pat Zanzonico,Jorge A. Carrasquillo,Jorge A. Carrasquillo,Serge K. Lyashchenko,Serge K. Lyashchenko,Sunitha B. Thakur,Maria Donzelli,Ryan S Turner,Jason S. Lewis,Nai-Kong V. Cheung,Steven M. Larson,Ira J. Dunkel,Ira J. Dunkel +22 more
TL;DR: PET-based dosimetry of the radiolabelled antibody [124I]-8H9 validated the principle of using convection-enhanced delivery in the brain to achieve high intra-lesional dosing with negligible systemic exposure in children with diffuse intrinsic pontine glioma.
Vemurafenib Redifferentiation of BRAF Mutant, RAI-Refractory Thyroid Cancers.
Lara Dunn,Lara Dunn,Eric J. Sherman,Eric J. Sherman,Shrujal S. Baxi,Shrujal S. Baxi,Vatche Tchekmedyian,Ravinder K. Grewal,Steven M. Larson,Keith S. Pentlow,Sofia Haque,R. Michael Tuttle,Mona M. Sabra,Stephanie Fish,Laura Boucai,Jamie Walters,Ronald Ghossein,Venkatraman E. Seshan,Ai Ni,Duan Li,Jeffrey A. Knauf,David G. Pfister,David G. Pfister,James A. Fagin,James A. Fagin,Alan L. Ho,Alan L. Ho +26 more
TL;DR: Higher baseline thyroglobulin values among responders suggest that tumor differentiation status may be a predictor of vemurafenib benefit, and restores RAI uptake and efficacy in a subset of BRAF mutant RAIR patients, probably by upregulating thyroid-specific gene expression via MAPK pathway inhibition.
Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation
Susan E. Prockop,Ekaterina Doubrovina,Stephanie Suser,Glenn Heller,Juliet N. Barker,Parastoo B. Dahi,Miguel Perales,Esperanza B. Papadopoulos,Craig S. Sauter,Hugo Castro-Malaspina,Farid Boulad,Kevin J. Curran,Sergio Giralt,Boglarka Gyurkocza,Katharine C. Hsu,Ann A. Jakubowski,Alan M. Hanash,Nancy A. Kernan,Rachel Kobos,G. Koehne,Heather Landau,Doris M. Ponce,Barbara Spitzer,James W. Young,Gerald Behr,Mark Dunphy,Sofia Haque,Julie Teruya-Feldstein,Maria E. Arcila,Christine Moung,Susan Hsu,Aisha Hasan,Richard J. O'Reilly +32 more
TL;DR: Third party EBV-CTLs of defined HLA restriction provide safe, immediately accessible treatment for EBV PTLD and suggest a promising potential therapy for patients with rituximab refractoryEBV-associated lymphoma post transplant.